View ValuationPhysitrack 将来の成長Future 基準チェック /16 Physitrackは収益が増加すると予測されています。主要情報n/a収益成長率n/aEPS成長率Healthcare Services 収益成長24.1%収益成長率10.9%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日24 Apr 2026今後の成長に関する最新情報Major Estimate Revision • Mar 31Consensus EPS estimates upgraded to €0.025 lossThe consensus outlook for fiscal year 2022 has been updated. 2022 losses forecast to reduce from -€0.037 to -€0.025 per share. Revenue forecast steady at €12.4m. Healthcare Services industry in Sweden expected to see average net income growth of 176% next year. Consensus price target broadly unchanged at kr40.13. Share price rose 12% to kr14.50 over the past week.お知らせ • Jan 27Physitrack PLC Provides Earnings GuidancePhysitrack PLC announced that the company's aims to achieve annual organic sales growth exceeding 30% in the medium term, further supplemented by impact from future add-on acquisitions.すべての更新を表示Recent updatesRecent Insider Transactions • May 18Chairman & Senior Independent Director recently bought kr52k worth of stockOn the 15th of May, Anne-Sophie d'Andlau bought around 7k shares on-market at roughly kr8.01 per share. This transaction amounted to 41% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Anne-Sophie's only on-market trade for the last 12 months.Reported Earnings • Apr 24First quarter 2026 earnings releasedFirst quarter 2026 results: Revenue: €3.24m (down 8.9% from 1Q 2025). Net income: €58.4k (up €465.1k from 1Q 2025). Profit margin: 1.8% (up from net loss in 1Q 2025). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Healthcare Services industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 90 percentage points per year, which is a significant difference in performance.New Risk • Mar 31New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 8.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 47% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.9% average weekly change). Market cap is less than US$100m (kr149.6m market cap, or US$15.6m).Reported Earnings • Mar 02Full year 2025 earnings released: €0.41 loss per share (vs €0.40 loss in FY 2024)Full year 2025 results: €0.41 loss per share (further deteriorated from €0.40 loss in FY 2024). Revenue: €13.5m (down 16% from FY 2024). Net loss: €6.61m (loss widened 2.4% from FY 2024). Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Healthcare Services industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 77 percentage points per year, which is a significant difference in performance.お知らせ • Feb 16Physitrack PLC, Annual General Meeting, May 26, 2026Physitrack PLC, Annual General Meeting, May 26, 2026, at 09:30 W. Europe Standard Time.分析記事 • Feb 12Little Excitement Around Physitrack PLC's (STO:PTRK) Revenues As Shares Take 28% PoundingUnfortunately for some shareholders, the Physitrack PLC ( STO:PTRK ) share price has dived 28% in the last thirty days...分析記事 • Feb 03Returns On Capital At Physitrack (STO:PTRK) Paint A Concerning PictureWhat are the early trends we should look for to identify a stock that could multiply in value over the long term...お知らせ • Jan 07+ 4 more updatesPhysitrack PLC Announces Chief Financial Officer ChangesPhysitrack PLC announced that Matthew Poulter has been appointed Chief Financial Officer (CFO) on a permanent basis. Matthew has served as Interim CFO since 1 April 2025 and has been Head of Finance at Physitrack since June 2021. Charlotte Goodwin has transitioned out of the company to pursue other opportunities.Board Change • Jan 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Chairman & Senior Independent Director Anne-Sophie d'Andlau was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.分析記事 • Dec 03Is Physitrack (STO:PTRK) A Risky Investment?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Oct 28Physitrack's (STO:PTRK) Returns On Capital Not Reflecting Well On The BusinessDid you know there are some financial metrics that can provide clues of a potential multi-bagger? One common approach...Reported Earnings • Oct 22Third quarter 2025 earnings released: €0.02 loss per share (vs €0.023 loss in 3Q 2024)Third quarter 2025 results: €0.02 loss per share (improved from €0.023 loss in 3Q 2024). Revenue: €3.46m (down 11% from 3Q 2024). Net loss: €354.4k (loss narrowed 5.8% from 3Q 2024). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Healthcare Services industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 71 percentage points per year, which is a significant difference in performance.分析記事 • Aug 05Physitrack PLC's (STO:PTRK) 32% Price Boost Is Out Of Tune With RevenuesOM:PTRK 1 Year Share Price vs Fair Value Explore Physitrack's Fair Values from the Community and select yours...Reported Earnings • Jul 25Second quarter 2025 earnings released: €0.01 loss per share (vs €0.029 loss in 2Q 2024)Second quarter 2025 results: €0.01 loss per share (improved from €0.029 loss in 2Q 2024). Revenue: €3.51m (down 11% from 2Q 2024). Net loss: €150.4k (loss narrowed 68% from 2Q 2024). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Healthcare Services industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 41 percentage points per year, which is a significant difference in performance.分析記事 • Jun 20Subdued Growth No Barrier To Physitrack PLC (STO:PTRK) With Shares Advancing 28%Physitrack PLC ( STO:PTRK ) shares have continued their recent momentum with a 28% gain in the last month alone. The...分析記事 • Jun 01Is Physitrack (STO:PTRK) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Reported Earnings • May 02First quarter 2025 earnings released: €0.03 loss per share (vs €0.007 loss in 1Q 2024)First quarter 2025 results: €0.03 loss per share (further deteriorated from €0.007 loss in 1Q 2024). Revenue: €3.56m (down 14% from 1Q 2024). Net loss: €406.7k (loss widened 267% from 1Q 2024). Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Healthcare Services industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 33% per year whereas the company’s share price has fallen by 30% per year.お知らせ • Apr 08Physitrack PLC, Annual General Meeting, Jun 27, 2025Physitrack PLC, Annual General Meeting, Jun 27, 2025.分析記事 • Apr 08Physitrack PLC's (STO:PTRK) 26% Dip In Price Shows Sentiment Is Matching RevenuesPhysitrack PLC ( STO:PTRK ) shares have retraced a considerable 26% in the last month, reversing a fair amount of their...Reported Earnings • Apr 02Full year 2024 earnings released: €0.40 loss per share (vs €0.17 profit in FY 2023)Full year 2024 results: €0.40 loss per share (down from €0.17 profit in FY 2023). Revenue: €16.2m (up 9.7% from FY 2023). Net loss: €6.45m (down 329% from profit in FY 2023). Revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Healthcare Services industry in Sweden. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.お知らせ • Mar 30+ 1 more updateManagement of Wellnow Group acquired Wellnow Group GmbH from Physitrack PLC (OM:PTRK) €0.300001 million.Management of Wellnow Group acquired Wellnow Group GmbH from Physitrack PLC (OM:PTRK) €0.300001 million on March 28, 2025. The terms of the MBO are for an initial consideration of €1, with the remaining consideration being structured around a multi-year earn-out directly tied to profit generation within Wellnow, ensuring a performance-driven transition.An additional earn-out consideration will be in the region of €200,000 - €300,000. As part of the agreement, Wellnow co-founders Alexander Freitag and Enno Kuntze have departed the Physitrack Group. Financially, the transaction is accretive to EBITDA margins and will, excluding earn-outs, generate annual cost savings. Management of Wellnow Group completed the acquisition of Wellnow Group GmbH from Physitrack PLC (OM:PTRK) on March 28, 2025.お知らせ • Mar 25Physitrack plc Announces Chief Financial Officer ChangesPhysitrack PLC announced that Chief Financial Officer Charlotte Goodwin will be going on maternity leave starting April 1, 2025. During her leave, Matt Poulter, Deputy CFO and a key member of the Group Finance team for the past four years, will step in as Interim CFO. Matt Poulter has played a pivotal role in Physitrack's financial leadership, bringing extensive experience and a deep understanding of the company's operations. His expertise ensures a seamless transition, maintaining the company's strong financial oversight.お知らせ • Mar 06Physitrack Plc Launches Enhanced PhysiAssistant App with New Filming & Exercise Upload FeaturePhysitrack Plc announced the launch of a major enhancement to its PhysiAssistant app, a mobile solution designed to give healthcare providers greater flexibility in day-to-day patient care. The new patient filming and exercise upload feature enables clinicians to record and upload personalized exercise demonstrations, allowing for an unprecedented level of ultra-personalization in rehabilitation and treatment plans. The PhysiAssistant app, already a key tool for healthcare professionals, features a streamlined user interface for exercise prescription, making it possible to work hands-free with patients in a clinical setting. With today's update, practitioners can now capture video of exercises in real-time and seamlessly integrate them into the Physitrack ecosystem for onward prescription. The update also brings added benefits for patients, who can now view themselves performing exercises with professional guidance, helping them perfect their form and, in some cases, achieve more effective recovery outcomes. This launch is part of a broader series of innovations that Physitrack has introduced to its ecosystem in recent months, reinforcing its commitment to enhancing customer value and staying ahead in the digital healthcare space.Reported Earnings • Mar 02Full year 2024 earnings released: €0.40 loss per share (vs €0.20 profit in FY 2023)Full year 2024 results: €0.40 loss per share (down from €0.20 profit in FY 2023). Revenue: €16.2m (up 6.6% from FY 2023). Net loss: €6.45m (down 301% from profit in FY 2023). Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Healthcare Services industry in Sweden. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Feb 18Investor sentiment improves as stock rises 31%After last week's 31% share price gain to kr13.20, the stock trades at a trailing P/E ratio of 6.8x. Average forward P/E is 49x in the Healthcare Services industry in Europe. Total loss to shareholders of 70% over the past three years.分析記事 • Feb 06Physitrack PLC's (STO:PTRK) Price Is Right But Growth Is Lacking After Shares Rocket 28%Physitrack PLC ( STO:PTRK ) shareholders are no doubt pleased to see that the share price has bounced 28% in the last...分析記事 • Feb 05Is Physitrack (STO:PTRK) A Risky Investment?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Valuation Update With 7 Day Price Move • Feb 04Investor sentiment improves as stock rises 17%After last week's 17% share price gain to kr9.64, the stock trades at a trailing P/E ratio of 4.9x. Average forward P/E is 17x in the Healthcare Services industry in Europe. Total loss to shareholders of 81% over the past three years.お知らせ • Dec 23+ 3 more updatesPhysitrack PLC to Report Q4, 2025 Results on Feb 28, 2026Physitrack PLC announced that they will report Q4, 2025 results on Feb 28, 2026分析記事 • Nov 20Investors Shouldn't Be Too Comfortable With Physitrack's (STO:PTRK) EarningsInvestors were disappointed with Physitrack PLC's ( STO:PTRK ) earnings, despite the strong profit numbers. We did some...Reported Earnings • Nov 13Third quarter 2024 earnings released: €0.02 loss per share (vs €0.015 loss in 3Q 2023)Third quarter 2024 results: €0.02 loss per share (further deteriorated from €0.015 loss in 3Q 2023). Revenue: €3.89m (flat on 3Q 2023). Net loss: €376.2k (loss widened 57% from 3Q 2023). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Sweden. Over the last 3 years on average, earnings per share has increased by 120% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings.分析記事 • Nov 13Positive Sentiment Still Eludes Physitrack PLC (STO:PTRK) Following 28% Share Price SlumpPhysitrack PLC ( STO:PTRK ) shareholders that were waiting for something to happen have been dealt a blow with a 28...分析記事 • Nov 13Positive Sentiment Still Eludes Physitrack PLC (STO:PTRK) Following 28% Share Price SlumpPhysitrack PLC ( STO:PTRK ) shareholders that were waiting for something to happen have been dealt a blow with a 28...New Risk • Nov 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.5% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (kr195.9m market cap, or US$18.0m).Valuation Update With 7 Day Price Move • Nov 12Investor sentiment deteriorates as stock falls 22%After last week's 22% share price decline to kr9.40, the stock trades at a trailing P/E ratio of 4.5x. Average forward P/E is 16x in the Healthcare Services industry in Europe. Total loss to shareholders of 82% over the past three years.Recent Insider Transactions • Oct 07Chairman & Senior Independent Director recently bought kr51k worth of stockOn the 4th of October, Anne-Sophie d'Andlau bought around 4k shares on-market at roughly kr12.83 per share. This transaction amounted to 33% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Anne-Sophie has been a buyer over the last 12 months, purchasing a net total of kr108k worth in shares.Reported Earnings • Aug 18Second quarter 2024 earnings released: €0.029 loss per share (vs €0.015 loss in 2Q 2023)Second quarter 2024 results: €0.029 loss per share (further deteriorated from €0.015 loss in 2Q 2023). Revenue: €3.96m (up 5.5% from 2Q 2023). Net loss: €471.0k (loss widened 87% from 2Q 2023). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Healthcare Services industry in Sweden. Over the last 3 years on average, earnings per share has increased by 106% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Jun 17Investor sentiment improves as stock rises 16%After last week's 16% share price gain to kr18.10, the stock trades at a trailing P/E ratio of 8.3x. Average forward P/E is 18x in the Healthcare Services industry in Europe. Total loss to shareholders of 62% over the past three years.分析記事 • Jun 15Investors Aren't Entirely Convinced By Physitrack PLC's (STO:PTRK) RevenuesThere wouldn't be many who think Physitrack PLC's ( STO:PTRK ) price-to-sales (or "P/S") ratio of 1.7x is worth a...Recent Insider Transactions • Jun 03Chairman & Senior Independent Director recently bought kr57k worth of stockOn the 30th of May, Anne-Sophie d'Andlau bought around 4k shares on-market at roughly kr14.14 per share. This transaction amounted to 50% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Anne-Sophie has been a buyer over the last 12 months, purchasing a net total of kr89k worth in shares.Reported Earnings • May 15First quarter 2024 earnings released: €0.01 loss per share (vs €0.004 loss in 1Q 2023)First quarter 2024 results: €0.01 loss per share (further deteriorated from €0.004 loss in 1Q 2023). Revenue: €4.12m (up 10% from 1Q 2023). Net loss: €110.8k (loss widened 69% from 1Q 2023). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Healthcare Services industry in Sweden.Valuation Update With 7 Day Price Move • May 11Investor sentiment improves as stock rises 16%After last week's 16% share price gain to kr16.30, the stock trades at a trailing P/E ratio of 7.1x. Average forward P/E is 19x in the Healthcare Services industry in Europe. Negligible returns to shareholders over past year.分析記事 • May 09Physitrack (STO:PTRK) Is Doing The Right Things To Multiply Its Share PriceDid you know there are some financial metrics that can provide clues of a potential multi-bagger? One common approach...分析記事 • Apr 10Physitrack (STO:PTRK) Has A Somewhat Strained Balance SheetWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...New Risk • Mar 07New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 4,900% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (kr200.0m market cap, or US$19.4m).Valuation Update With 7 Day Price Move • Mar 06Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to kr12.60, the stock trades at a trailing P/E ratio of 5.7x. Average forward P/E is 17x in the Healthcare Services industry in Sweden. Total loss to shareholders of 17% over the past year.Reported Earnings • Mar 01Full year 2023 earnings released: EPS: €0.20 (vs €0.006 in FY 2022)Full year 2023 results: EPS: €0.20 (up from €0.006 in FY 2022). Revenue: €15.2m (up 21% from FY 2022). Net income: €3.20m (up €3.11m from FY 2022). Profit margin: 21% (up from 0.7% in FY 2022). The increase in margin was primarily driven by higher revenue. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Sweden.分析記事 • Feb 29Physitrack PLC (STO:PTRK) Could Be Riskier Than It LooksIt's not a stretch to say that Physitrack PLC's ( STO:PTRK ) price-to-sales (or "P/S") ratio of 1.3x right now seems...お知らせ • Feb 13Physitrack PLC, Annual General Meeting, May 03, 2024Physitrack PLC, Annual General Meeting, May 03, 2024.お知らせ • Dec 23+ 3 more updatesPhysitrack PLC to Report Q4, 2024 Results on Feb 28, 2025Physitrack PLC announced that they will report Q4, 2024 results on Feb 28, 2025New Risk • Nov 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (kr268.3m market cap, or US$25.7m).Reported Earnings • Nov 15Third quarter 2023 earnings released: €0.01 loss per share (vs €0.001 profit in 3Q 2022)Third quarter 2023 results: €0.01 loss per share (down from €0.001 profit in 3Q 2022). Revenue: €3.85m (up 14% from 3Q 2022). Net loss: €240.2k (down €256.8k from profit in 3Q 2022). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Healthcare Services industry in Sweden.分析記事 • Oct 12Revenues Tell The Story For Physitrack PLC (STO:PTRK)It's not a stretch to say that Physitrack PLC's ( STO:PTRK ) price-to-sales (or "P/S") ratio of 1.8x seems quite...分析記事 • Aug 18Why Physitrack PLC (STO:PTRK) Could Be Worth WatchingPhysitrack PLC ( STO:PTRK ), is not the largest company out there, but it saw a double-digit share price rise of over...Reported Earnings • Aug 17Second quarter 2023 earnings released: €0.015 loss per share (vs €0.026 loss in 2Q 2022)Second quarter 2023 results: €0.015 loss per share (improved from €0.026 loss in 2Q 2022). Revenue: €3.75m (up 23% from 2Q 2022). Net loss: €251.7k (loss narrowed 40% from 2Q 2022). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Healthcare Services industry in Sweden.New Risk • Aug 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (kr269.1m market cap, or US$24.8m).お知らせ • Aug 15Physitrack plc Announces Board ChangesPhysitrack PLC appointed Mrs. Anne-Sophie D'Andlau, formerly Vice Chair, as Chair of the Board with effect from September 15, 2023. Anne-Sophie will be replacing Mrs. Elaine Sullivan who has decided to resign from her position as an independent non-executive director and the Chair of the Board with effect from 15 September, 2023 to consider other opportunities. Elaine Sullivan has served as an independent non-executive director and the Chair of the Board since March 9, 2021, seeing the Company through its successful transition into a Plc and initial public offering on the Nasdaq First North Growth Premier Market on 18 June 2021.お知らせ • Jun 03Physitrack PLC Announces Appointment of Jack Goodwin as Head of PeoplePhysitrack PLC announced the appointment of Mr. Jack Goodwin as Head of People for the Physitrack Group. Mr. Goodwin joins the Company from the UK Government's Cabinet Office, where he last oversaw a transformation programme for 330,000 employees under the Arm's-Length Bodies and was responsible for policy advice to the Cabinet Office and His Majesty's Treasury Ministers. The appointment of Mr. Goodwin to oversee everything People and HR related provides the Company with an opportunity to streamline the company at Group level for operational and financial efficiency and Physitrack therefore at the same time also announces that it will reduce its C-suite with two people, whose roles overlap significantly with that of the Head of People function. Further to the appointment of Jack Goodwin, departing the C-suite as of but remaining with the Company for a transition period are Mr. Andrew Knox, Group Chief Operating Officer and Mr. Ryan Ebert, Chief Commercial Officer, Wellness. Ryan and Andrew will both ensure a smooth handover to Mr. Goodwin as the Physitrack Group continues on its journey.お知らせ • May 04Physitrack PLC Approves Election of Anne-Sophie D'andlau as DirectorPhysitrack PLC approved election of Anne-Sophie D'Andlau as a Director of the Company at the Annual General Meeting held on May 3, 2023.Reported Earnings • May 03First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: €3.73m (up 45% from 1Q 2022). Net loss: €65.6k (loss narrowed 55% from 1Q 2022). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Healthcare Services industry in Sweden.Recent Insider Transactions • Apr 05Independent Non-Executive Director recently bought kr56k worth of stockOn the 31st of March, Anne-Sophie d'Andlau bought around 4k shares on-market at roughly kr13.92 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold kr10.0m more in shares than they bought in the last 12 months.Major Estimate Revision • Mar 31Consensus EPS estimates upgraded to €0.025 lossThe consensus outlook for fiscal year 2022 has been updated. 2022 losses forecast to reduce from -€0.037 to -€0.025 per share. Revenue forecast steady at €12.4m. Healthcare Services industry in Sweden expected to see average net income growth of 176% next year. Consensus price target broadly unchanged at kr40.13. Share price rose 12% to kr14.50 over the past week.Reported Earnings • Mar 02Full year 2022 earnings released: EPS: €0.01 (vs €0.06 loss in FY 2021)Full year 2022 results: EPS: €0.01 (up from €0.06 loss in FY 2021). Revenue: €12.5m (up 60% from FY 2021). Net income: €92.3k (up €907.4k from FY 2021). Profit margin: 0.7% (up from net loss in FY 2021). The move to profitability was driven by higher revenue. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Sweden.分析記事 • Jan 29Be Wary Of Physitrack (STO:PTRK) And Its Returns On CapitalDid you know there are some financial metrics that can provide clues of a potential multi-bagger? Amongst other things...お知らせ • Jan 27Physitrack PLC Appoints Nick McClelland to Take on A New Role as Chief Growth OfficerPhysitrack PLC appointed Nick McClelland from Mercer to take on a new role as Chief Growth Officer of Champion Health with the objective of further accelerating the growth of Group's B2B Wellness division. Nick McClelland will lead and build on Champion Health's sales team for B2B sales of Champion's rapidly growing Employee Wellbeing solution to Enterprises as well as further develop Group level business development to continue accelerating the growth of both Champion Health and the Physitrack Group. Prior to joining Champion Health, Nick McClelland was Chief Growth Officer of Mercer UK, part of $82 billion market capitalisation global insurance giant Marsh McLennan, and prior to that led the commercial efforts of JLT Employee Benefits and Thompsons Online Benefits, which provided technology-led employee benefit and wellness solutions to Enterprises globally before both companies were acquired by Mercer. Nick is set to commence in his new role on 1 February 2023.Board Change • Jan 01High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Co-Founder, CEO & Executive Director Henrik Molin is the most experienced director on the board, commencing their role in 2012. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.お知らせ • Dec 21Physitrack PLC Announces the Appoints Anne-Sophie d'Andlau as Board MemberPhysitrack PLC announced the appointment of Mrs. Anne-Sophie d'Andlau to the board of directors as an independent non-executive director, effective immediately. Mrs. d'Andlau has also been appointed as a member of Physitrack Plc's nomination and audit committees. Anne-Sophie d'Andlau is the co-founder of CIAM, a corporate events-focused investment management firm that takes an active approach to equity-based investment strategies. Prior to co-founding CIAM, Anne-Sophie was the Head of Event Driven Strategies at Systeia Capital Management in Paris 2001-2008. Prior to that, Anne-Sophie spent six years with PwC in Paris and New York focused on audit, due diligence and M&A advisory. She has a degree in Corporate Finance from NEOMA Business School.Reported Earnings • Nov 08Third quarter 2022 earnings released: EPS: €0.001 (vs €0.07 loss in 3Q 2021)Third quarter 2022 results: EPS: €0.001 (up from €0.07 loss in 3Q 2021). Revenue: €3.37m (up 69% from 3Q 2021). Net income: €16.7k (up €898.8k from 3Q 2021). Profit margin: 0.5% (up from net loss in 3Q 2021). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Healthcare Services industry in Sweden.お知らせ • Nov 07+ 4 more updatesPhysitrack PLC to Report Q2, 2023 Results on Aug 15, 2023Physitrack PLC announced that they will report Q2, 2023 results on Aug 15, 2023分析記事 • Oct 29Physitrack (STO:PTRK) Will Be Hoping To Turn Its Returns On Capital AroundTo find a multi-bagger stock, what are the underlying trends we should look for in a business? In a perfect world, we'd...お知らせ • Aug 31Henrik Molin, Chief Executive Officer and Co-founder of Physitrack PLC acquired an additional 4.3% stake in Physitrack PLC (OM : PTRK) from Nathan Skwortsow, co-founder of Physitrack PLC for €1 million.Henrik Molin, Chief Executive Officer and Co-founder of Physitrack PLC acquired an additional 4.3% stake in Physitrack PLC (OM : PTRK) from Nathan Skwortsow, co-founder of Physitrack PLC for €1 million on August 29, 2022. Under the terms of the transaction, Henrik Molin acquired 0.7 million shares Physitrack PLC from Nathan Skwortsow. As a result of the transaction, Henrik Molin boosts its ownership to 24.7% and reduces Nathan Skwortsow’s ownership to 17.8%. in Physitrack PLC.Henrik Molin, Chief Executive Officer and Co-founder of Physitrack PLC completed the acquisition of an additional 4.3% stake in Physitrack PLC (OM : PTRK) from Nathan Skwortsow, co-founder of Physitrack PLC on August 29, 2022.Reported Earnings • Aug 25Second quarter 2022 earnings released: €0.02 loss per share (vs €0.011 loss in 2Q 2021)Second quarter 2022 results: €0.02 loss per share (down from €0.011 loss in 2Q 2021). Revenue: €3.05m (up 76% from 2Q 2021). Net loss: €421.0k (loss widened 240% from 2Q 2021). Over the next year, revenue is forecast to grow 48%, compared to a 16% growth forecast for the Healthcare Services industry in Sweden.お知らせ • Aug 11Physitrack plc Recruits Announces Management ChangesPhysitrack PLC boosts its management team and recruits Michal Wegrzyn from Zendesk. Michal Wegrzyn will take on a new role as Head of Engineering at Physitrack. As a result of the recruitments, co-founder and CTO Nathan Skwortsow will take on a new position focused on sourcing and developing new business ventures on behalf of the company. Michal Wegrzyn, who prior to joining Physitrack was an Engineering Manager at NYSE-listed$10bln market leader in customer support SaaS provider Zendesk, has been recruited as Head of Engineering. Michal will lead a new team of in-house Ruby on Rails, Mobile and DevOps developers, as Physitrack transitions away from its previous inhouse/outsource hybrid software development model. The new setup will not only benefit Physitrack from an efficiency and cultural standpoint but will also optimize the cost of investments in Physitrack's platform.As a result of the recruitments, co-founder and CTO Nathan Skwortsow will take on a new position in Physitrack's management team focused on sourcing and developing new business ventures on behalf of the company.Recent Insider Transactions • Jun 03Chief Operating Officer recently bought kr56k worth of stockOn the 30th of May, Andrew Knox bought around 1k shares on-market at roughly kr42.99 per share. This was the largest purchase by an insider in the last 3 months. Andrew has been a buyer over the last 12 months, purchasing a net total of kr108k worth in shares.Reported Earnings • May 26First quarter 2022 earnings: Revenues miss analyst expectationsFirst quarter 2022 results: Revenue: €2.58m (up 63% from 1Q 2021). Net loss: €145.7k (down 177% from profit in 1Q 2021). Revenue missed analyst estimates by 2.9%. Over the next year, revenue is forecast to grow 58%, compared to a 19% growth forecast for the industry in Sweden.お知らせ • May 08Physitrack PLC (OM:PTRK) acquired Champion Health Ltd from Harry Bliss and Ricky Bailey for £10.4 million.Physitrack PLC (OM:PTRK) acquired Champion Health Ltd from Harry Bliss and Ricky Bailey for £10.4 million on May 6, 2022. Physitrack will pay a total cash consideration of £2.5 million upfront for the acquisition, and a further potential aggregate earn-out consideration of up to £7.894 million over four years, subject to Champion achieving stretching growth and profitability targets in that period. The deal is financed with cash. Post-completion, Champion's successful wellbeing platform and innovative technology will continue to be accessible as a standalone product and will over time see the integration of Physitrack's Access ecosystem. Champion Health Ltd had gross assets of €0.3 million (£0.25 million) and revenue of €0.1 million (£0.08 million) for the year ended December 31, 2021. The management team of Champion, including co-founders Harry Bliss, Chief Executive Officer of Champion and Ricky Bailey, Chief Development Officer of Champion, their team of wellbeing and tech experts, as well as their network of skilled contributors and certified health practitioners will join Physitrack. The closing of the transaction is not subject to any closing conditions, including no regulatory approvals. The acquisition of Champion is a financially accretive deal. Paul Berwin and team of Berwins LLP acted as legal advisor to the founder shareholders. Physitrack PLC (OM:PTRK) completed the acquisition of Champion Health Ltd from Harry Bliss and Ricky Bailey on May 6, 2022.Reported Earnings • Mar 01Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2021 results: €0.06 loss per share (down from €0.069 profit in FY 2020). Revenue: €7.81m (up 156% from FY 2020). Net loss: €815.0k (down 218% from profit in FY 2020). Revenue exceeded analyst estimates by 1.6%. Earnings per share (EPS) missed analyst estimates. Over the next year, revenue is forecast to grow 60%, compared to a 17% growth forecast for the industry in Sweden.Recent Insider Transactions • Feb 26Chief Financial Officer recently bought kr62k worth of stockOn the 24th of February, Charlotte Goodwin bought around 1k shares on-market at roughly kr45.00 per share. This was the largest purchase by an insider in the last 3 months. This was Charlotte's only on-market trade for the last 12 months.お知らせ • Feb 25+ 1 more updatePhysitrack PLC (OM:PTRK) acquired Wellnow Group GmbH from Axel Springer Plug and Play Accelerator GmbH and Tengelmann Ventures Management GmbH for €11.5 million.Physitrack PLC (OM:PTRK) acquired Wellnow Group GmbH from Axel Springer Plug and Play Accelerator GmbH and Tengelmann Ventures Management GmbH for €11.5 million on February 23, 2022. Physitrack will pay a total cash consideration of €2.5 million for the acquisition and a further potential aggregate earn-out consideration of up to €9 million over four years, subject to Wellnow achieving stretching growth targets in that period that are in alignment with Physitrack’s. In the twelve months ending December 31, 2021, Wellnow delivered revenue of €0.4 million. At 31 December 2021, Wellnow´s gross assets were EUR 0.3 million. Physitrack PLC (OM:PTRK) completed the acquisition of Wellnow Group GmbH from Axel Springer Plug and Play Accelerator GmbH and Tengelmann Ventures Management GmbH on February 23, 2022.Reported Earnings • Jan 27Full year 2021 earnings: EPS exceeds analyst expectationsFull year 2021 results: €0.05 loss per share (down from €0.069 profit in FY 2020). Revenue: €7.72m (up 153% from FY 2020). Net loss: €635.0k (down 192% from profit in FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 75%. Over the next year, revenue is forecast to grow 48%, compared to a 19% growth forecast for the industry in Sweden.お知らせ • Jan 27Physitrack PLC Provides Earnings GuidancePhysitrack PLC announced that the company's aims to achieve annual organic sales growth exceeding 30% in the medium term, further supplemented by impact from future add-on acquisitions.Valuation Update With 7 Day Price Move • Jul 04Investor sentiment improved over the past weekAfter last week's 21% share price gain to €50.40, the stock trades at a trailing P/E ratio of 72.3x. Average trailing P/E is 45x in the Healthcare Services industry in Europe.お知らせ • Jun 19Physitrack PLC has completed an IPO in the amount of SEK 175 million.Physitrack PLC has completed an IPO in the amount of SEK 175 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 4,375,000 Price\Range: SEK 40業績と収益の成長予測OM:PTRK - アナリストの将来予測と過去の財務データ ( )EUR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202818N/AN/A7112/31/202716N/AN/A6112/31/202614N/AN/A513/31/202614-614N/A12/31/202514-714N/A9/30/202513014N/A6/30/202513014N/A3/31/202513003N/A12/31/202414003N/A9/30/202414203N/A6/30/202414203N/A3/31/202415303N/A12/31/2023153-13N/A9/30/2023150-22N/A6/30/2023140-22N/A3/31/2023140-32N/A12/31/2022130-31N/A9/30/2022110-31N/A6/30/2022100-30N/A3/31/20229-1-20N/A12/31/20218-1-11N/A11/30/20218-1-11N/A8/31/20216-101N/A5/31/20215112N/A2/28/20214112N/A11/30/20203112N/A11/30/201910N/A1N/A11/30/201810N/AN/AN/A11/30/201700N/AN/AN/A11/30/201600N/AN/AN/A11/30/201500N/AN/AN/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: PTRKの予測収益成長が 貯蓄率 ( 2% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: PTRKの収益がSwedish市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: PTRKの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: PTRKの収益 ( 10.9% ) Swedish市場 ( -0.04% ) よりも速いペースで成長すると予測されています。高い収益成長: PTRKの収益 ( 10.9% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: PTRKの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/11 07:48終値2026/06/11 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Physitrack PLC 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Rebecka GärderupABG Sundal Collier SponsoredJoachim GunellDNB CarnegieJessica GrunewaldRedeye
Major Estimate Revision • Mar 31Consensus EPS estimates upgraded to €0.025 lossThe consensus outlook for fiscal year 2022 has been updated. 2022 losses forecast to reduce from -€0.037 to -€0.025 per share. Revenue forecast steady at €12.4m. Healthcare Services industry in Sweden expected to see average net income growth of 176% next year. Consensus price target broadly unchanged at kr40.13. Share price rose 12% to kr14.50 over the past week.
お知らせ • Jan 27Physitrack PLC Provides Earnings GuidancePhysitrack PLC announced that the company's aims to achieve annual organic sales growth exceeding 30% in the medium term, further supplemented by impact from future add-on acquisitions.
Recent Insider Transactions • May 18Chairman & Senior Independent Director recently bought kr52k worth of stockOn the 15th of May, Anne-Sophie d'Andlau bought around 7k shares on-market at roughly kr8.01 per share. This transaction amounted to 41% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Anne-Sophie's only on-market trade for the last 12 months.
Reported Earnings • Apr 24First quarter 2026 earnings releasedFirst quarter 2026 results: Revenue: €3.24m (down 8.9% from 1Q 2025). Net income: €58.4k (up €465.1k from 1Q 2025). Profit margin: 1.8% (up from net loss in 1Q 2025). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Healthcare Services industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 90 percentage points per year, which is a significant difference in performance.
New Risk • Mar 31New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 8.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 47% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.9% average weekly change). Market cap is less than US$100m (kr149.6m market cap, or US$15.6m).
Reported Earnings • Mar 02Full year 2025 earnings released: €0.41 loss per share (vs €0.40 loss in FY 2024)Full year 2025 results: €0.41 loss per share (further deteriorated from €0.40 loss in FY 2024). Revenue: €13.5m (down 16% from FY 2024). Net loss: €6.61m (loss widened 2.4% from FY 2024). Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Healthcare Services industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 77 percentage points per year, which is a significant difference in performance.
お知らせ • Feb 16Physitrack PLC, Annual General Meeting, May 26, 2026Physitrack PLC, Annual General Meeting, May 26, 2026, at 09:30 W. Europe Standard Time.
分析記事 • Feb 12Little Excitement Around Physitrack PLC's (STO:PTRK) Revenues As Shares Take 28% PoundingUnfortunately for some shareholders, the Physitrack PLC ( STO:PTRK ) share price has dived 28% in the last thirty days...
分析記事 • Feb 03Returns On Capital At Physitrack (STO:PTRK) Paint A Concerning PictureWhat are the early trends we should look for to identify a stock that could multiply in value over the long term...
お知らせ • Jan 07+ 4 more updatesPhysitrack PLC Announces Chief Financial Officer ChangesPhysitrack PLC announced that Matthew Poulter has been appointed Chief Financial Officer (CFO) on a permanent basis. Matthew has served as Interim CFO since 1 April 2025 and has been Head of Finance at Physitrack since June 2021. Charlotte Goodwin has transitioned out of the company to pursue other opportunities.
Board Change • Jan 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Chairman & Senior Independent Director Anne-Sophie d'Andlau was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
分析記事 • Dec 03Is Physitrack (STO:PTRK) A Risky Investment?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
分析記事 • Oct 28Physitrack's (STO:PTRK) Returns On Capital Not Reflecting Well On The BusinessDid you know there are some financial metrics that can provide clues of a potential multi-bagger? One common approach...
Reported Earnings • Oct 22Third quarter 2025 earnings released: €0.02 loss per share (vs €0.023 loss in 3Q 2024)Third quarter 2025 results: €0.02 loss per share (improved from €0.023 loss in 3Q 2024). Revenue: €3.46m (down 11% from 3Q 2024). Net loss: €354.4k (loss narrowed 5.8% from 3Q 2024). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Healthcare Services industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 71 percentage points per year, which is a significant difference in performance.
分析記事 • Aug 05Physitrack PLC's (STO:PTRK) 32% Price Boost Is Out Of Tune With RevenuesOM:PTRK 1 Year Share Price vs Fair Value Explore Physitrack's Fair Values from the Community and select yours...
Reported Earnings • Jul 25Second quarter 2025 earnings released: €0.01 loss per share (vs €0.029 loss in 2Q 2024)Second quarter 2025 results: €0.01 loss per share (improved from €0.029 loss in 2Q 2024). Revenue: €3.51m (down 11% from 2Q 2024). Net loss: €150.4k (loss narrowed 68% from 2Q 2024). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Healthcare Services industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 41 percentage points per year, which is a significant difference in performance.
分析記事 • Jun 20Subdued Growth No Barrier To Physitrack PLC (STO:PTRK) With Shares Advancing 28%Physitrack PLC ( STO:PTRK ) shares have continued their recent momentum with a 28% gain in the last month alone. The...
分析記事 • Jun 01Is Physitrack (STO:PTRK) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Reported Earnings • May 02First quarter 2025 earnings released: €0.03 loss per share (vs €0.007 loss in 1Q 2024)First quarter 2025 results: €0.03 loss per share (further deteriorated from €0.007 loss in 1Q 2024). Revenue: €3.56m (down 14% from 1Q 2024). Net loss: €406.7k (loss widened 267% from 1Q 2024). Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Healthcare Services industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 33% per year whereas the company’s share price has fallen by 30% per year.
お知らせ • Apr 08Physitrack PLC, Annual General Meeting, Jun 27, 2025Physitrack PLC, Annual General Meeting, Jun 27, 2025.
分析記事 • Apr 08Physitrack PLC's (STO:PTRK) 26% Dip In Price Shows Sentiment Is Matching RevenuesPhysitrack PLC ( STO:PTRK ) shares have retraced a considerable 26% in the last month, reversing a fair amount of their...
Reported Earnings • Apr 02Full year 2024 earnings released: €0.40 loss per share (vs €0.17 profit in FY 2023)Full year 2024 results: €0.40 loss per share (down from €0.17 profit in FY 2023). Revenue: €16.2m (up 9.7% from FY 2023). Net loss: €6.45m (down 329% from profit in FY 2023). Revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Healthcare Services industry in Sweden. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings.
お知らせ • Mar 30+ 1 more updateManagement of Wellnow Group acquired Wellnow Group GmbH from Physitrack PLC (OM:PTRK) €0.300001 million.Management of Wellnow Group acquired Wellnow Group GmbH from Physitrack PLC (OM:PTRK) €0.300001 million on March 28, 2025. The terms of the MBO are for an initial consideration of €1, with the remaining consideration being structured around a multi-year earn-out directly tied to profit generation within Wellnow, ensuring a performance-driven transition.An additional earn-out consideration will be in the region of €200,000 - €300,000. As part of the agreement, Wellnow co-founders Alexander Freitag and Enno Kuntze have departed the Physitrack Group. Financially, the transaction is accretive to EBITDA margins and will, excluding earn-outs, generate annual cost savings. Management of Wellnow Group completed the acquisition of Wellnow Group GmbH from Physitrack PLC (OM:PTRK) on March 28, 2025.
お知らせ • Mar 25Physitrack plc Announces Chief Financial Officer ChangesPhysitrack PLC announced that Chief Financial Officer Charlotte Goodwin will be going on maternity leave starting April 1, 2025. During her leave, Matt Poulter, Deputy CFO and a key member of the Group Finance team for the past four years, will step in as Interim CFO. Matt Poulter has played a pivotal role in Physitrack's financial leadership, bringing extensive experience and a deep understanding of the company's operations. His expertise ensures a seamless transition, maintaining the company's strong financial oversight.
お知らせ • Mar 06Physitrack Plc Launches Enhanced PhysiAssistant App with New Filming & Exercise Upload FeaturePhysitrack Plc announced the launch of a major enhancement to its PhysiAssistant app, a mobile solution designed to give healthcare providers greater flexibility in day-to-day patient care. The new patient filming and exercise upload feature enables clinicians to record and upload personalized exercise demonstrations, allowing for an unprecedented level of ultra-personalization in rehabilitation and treatment plans. The PhysiAssistant app, already a key tool for healthcare professionals, features a streamlined user interface for exercise prescription, making it possible to work hands-free with patients in a clinical setting. With today's update, practitioners can now capture video of exercises in real-time and seamlessly integrate them into the Physitrack ecosystem for onward prescription. The update also brings added benefits for patients, who can now view themselves performing exercises with professional guidance, helping them perfect their form and, in some cases, achieve more effective recovery outcomes. This launch is part of a broader series of innovations that Physitrack has introduced to its ecosystem in recent months, reinforcing its commitment to enhancing customer value and staying ahead in the digital healthcare space.
Reported Earnings • Mar 02Full year 2024 earnings released: €0.40 loss per share (vs €0.20 profit in FY 2023)Full year 2024 results: €0.40 loss per share (down from €0.20 profit in FY 2023). Revenue: €16.2m (up 6.6% from FY 2023). Net loss: €6.45m (down 301% from profit in FY 2023). Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Healthcare Services industry in Sweden. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Feb 18Investor sentiment improves as stock rises 31%After last week's 31% share price gain to kr13.20, the stock trades at a trailing P/E ratio of 6.8x. Average forward P/E is 49x in the Healthcare Services industry in Europe. Total loss to shareholders of 70% over the past three years.
分析記事 • Feb 06Physitrack PLC's (STO:PTRK) Price Is Right But Growth Is Lacking After Shares Rocket 28%Physitrack PLC ( STO:PTRK ) shareholders are no doubt pleased to see that the share price has bounced 28% in the last...
分析記事 • Feb 05Is Physitrack (STO:PTRK) A Risky Investment?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Valuation Update With 7 Day Price Move • Feb 04Investor sentiment improves as stock rises 17%After last week's 17% share price gain to kr9.64, the stock trades at a trailing P/E ratio of 4.9x. Average forward P/E is 17x in the Healthcare Services industry in Europe. Total loss to shareholders of 81% over the past three years.
お知らせ • Dec 23+ 3 more updatesPhysitrack PLC to Report Q4, 2025 Results on Feb 28, 2026Physitrack PLC announced that they will report Q4, 2025 results on Feb 28, 2026
分析記事 • Nov 20Investors Shouldn't Be Too Comfortable With Physitrack's (STO:PTRK) EarningsInvestors were disappointed with Physitrack PLC's ( STO:PTRK ) earnings, despite the strong profit numbers. We did some...
Reported Earnings • Nov 13Third quarter 2024 earnings released: €0.02 loss per share (vs €0.015 loss in 3Q 2023)Third quarter 2024 results: €0.02 loss per share (further deteriorated from €0.015 loss in 3Q 2023). Revenue: €3.89m (flat on 3Q 2023). Net loss: €376.2k (loss widened 57% from 3Q 2023). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Sweden. Over the last 3 years on average, earnings per share has increased by 120% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings.
分析記事 • Nov 13Positive Sentiment Still Eludes Physitrack PLC (STO:PTRK) Following 28% Share Price SlumpPhysitrack PLC ( STO:PTRK ) shareholders that were waiting for something to happen have been dealt a blow with a 28...
分析記事 • Nov 13Positive Sentiment Still Eludes Physitrack PLC (STO:PTRK) Following 28% Share Price SlumpPhysitrack PLC ( STO:PTRK ) shareholders that were waiting for something to happen have been dealt a blow with a 28...
New Risk • Nov 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.5% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (kr195.9m market cap, or US$18.0m).
Valuation Update With 7 Day Price Move • Nov 12Investor sentiment deteriorates as stock falls 22%After last week's 22% share price decline to kr9.40, the stock trades at a trailing P/E ratio of 4.5x. Average forward P/E is 16x in the Healthcare Services industry in Europe. Total loss to shareholders of 82% over the past three years.
Recent Insider Transactions • Oct 07Chairman & Senior Independent Director recently bought kr51k worth of stockOn the 4th of October, Anne-Sophie d'Andlau bought around 4k shares on-market at roughly kr12.83 per share. This transaction amounted to 33% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Anne-Sophie has been a buyer over the last 12 months, purchasing a net total of kr108k worth in shares.
Reported Earnings • Aug 18Second quarter 2024 earnings released: €0.029 loss per share (vs €0.015 loss in 2Q 2023)Second quarter 2024 results: €0.029 loss per share (further deteriorated from €0.015 loss in 2Q 2023). Revenue: €3.96m (up 5.5% from 2Q 2023). Net loss: €471.0k (loss widened 87% from 2Q 2023). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Healthcare Services industry in Sweden. Over the last 3 years on average, earnings per share has increased by 106% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Jun 17Investor sentiment improves as stock rises 16%After last week's 16% share price gain to kr18.10, the stock trades at a trailing P/E ratio of 8.3x. Average forward P/E is 18x in the Healthcare Services industry in Europe. Total loss to shareholders of 62% over the past three years.
分析記事 • Jun 15Investors Aren't Entirely Convinced By Physitrack PLC's (STO:PTRK) RevenuesThere wouldn't be many who think Physitrack PLC's ( STO:PTRK ) price-to-sales (or "P/S") ratio of 1.7x is worth a...
Recent Insider Transactions • Jun 03Chairman & Senior Independent Director recently bought kr57k worth of stockOn the 30th of May, Anne-Sophie d'Andlau bought around 4k shares on-market at roughly kr14.14 per share. This transaction amounted to 50% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Anne-Sophie has been a buyer over the last 12 months, purchasing a net total of kr89k worth in shares.
Reported Earnings • May 15First quarter 2024 earnings released: €0.01 loss per share (vs €0.004 loss in 1Q 2023)First quarter 2024 results: €0.01 loss per share (further deteriorated from €0.004 loss in 1Q 2023). Revenue: €4.12m (up 10% from 1Q 2023). Net loss: €110.8k (loss widened 69% from 1Q 2023). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Healthcare Services industry in Sweden.
Valuation Update With 7 Day Price Move • May 11Investor sentiment improves as stock rises 16%After last week's 16% share price gain to kr16.30, the stock trades at a trailing P/E ratio of 7.1x. Average forward P/E is 19x in the Healthcare Services industry in Europe. Negligible returns to shareholders over past year.
分析記事 • May 09Physitrack (STO:PTRK) Is Doing The Right Things To Multiply Its Share PriceDid you know there are some financial metrics that can provide clues of a potential multi-bagger? One common approach...
分析記事 • Apr 10Physitrack (STO:PTRK) Has A Somewhat Strained Balance SheetWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
New Risk • Mar 07New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 4,900% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (kr200.0m market cap, or US$19.4m).
Valuation Update With 7 Day Price Move • Mar 06Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to kr12.60, the stock trades at a trailing P/E ratio of 5.7x. Average forward P/E is 17x in the Healthcare Services industry in Sweden. Total loss to shareholders of 17% over the past year.
Reported Earnings • Mar 01Full year 2023 earnings released: EPS: €0.20 (vs €0.006 in FY 2022)Full year 2023 results: EPS: €0.20 (up from €0.006 in FY 2022). Revenue: €15.2m (up 21% from FY 2022). Net income: €3.20m (up €3.11m from FY 2022). Profit margin: 21% (up from 0.7% in FY 2022). The increase in margin was primarily driven by higher revenue. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Sweden.
分析記事 • Feb 29Physitrack PLC (STO:PTRK) Could Be Riskier Than It LooksIt's not a stretch to say that Physitrack PLC's ( STO:PTRK ) price-to-sales (or "P/S") ratio of 1.3x right now seems...
お知らせ • Feb 13Physitrack PLC, Annual General Meeting, May 03, 2024Physitrack PLC, Annual General Meeting, May 03, 2024.
お知らせ • Dec 23+ 3 more updatesPhysitrack PLC to Report Q4, 2024 Results on Feb 28, 2025Physitrack PLC announced that they will report Q4, 2024 results on Feb 28, 2025
New Risk • Nov 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (kr268.3m market cap, or US$25.7m).
Reported Earnings • Nov 15Third quarter 2023 earnings released: €0.01 loss per share (vs €0.001 profit in 3Q 2022)Third quarter 2023 results: €0.01 loss per share (down from €0.001 profit in 3Q 2022). Revenue: €3.85m (up 14% from 3Q 2022). Net loss: €240.2k (down €256.8k from profit in 3Q 2022). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Healthcare Services industry in Sweden.
分析記事 • Oct 12Revenues Tell The Story For Physitrack PLC (STO:PTRK)It's not a stretch to say that Physitrack PLC's ( STO:PTRK ) price-to-sales (or "P/S") ratio of 1.8x seems quite...
分析記事 • Aug 18Why Physitrack PLC (STO:PTRK) Could Be Worth WatchingPhysitrack PLC ( STO:PTRK ), is not the largest company out there, but it saw a double-digit share price rise of over...
Reported Earnings • Aug 17Second quarter 2023 earnings released: €0.015 loss per share (vs €0.026 loss in 2Q 2022)Second quarter 2023 results: €0.015 loss per share (improved from €0.026 loss in 2Q 2022). Revenue: €3.75m (up 23% from 2Q 2022). Net loss: €251.7k (loss narrowed 40% from 2Q 2022). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Healthcare Services industry in Sweden.
New Risk • Aug 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (kr269.1m market cap, or US$24.8m).
お知らせ • Aug 15Physitrack plc Announces Board ChangesPhysitrack PLC appointed Mrs. Anne-Sophie D'Andlau, formerly Vice Chair, as Chair of the Board with effect from September 15, 2023. Anne-Sophie will be replacing Mrs. Elaine Sullivan who has decided to resign from her position as an independent non-executive director and the Chair of the Board with effect from 15 September, 2023 to consider other opportunities. Elaine Sullivan has served as an independent non-executive director and the Chair of the Board since March 9, 2021, seeing the Company through its successful transition into a Plc and initial public offering on the Nasdaq First North Growth Premier Market on 18 June 2021.
お知らせ • Jun 03Physitrack PLC Announces Appointment of Jack Goodwin as Head of PeoplePhysitrack PLC announced the appointment of Mr. Jack Goodwin as Head of People for the Physitrack Group. Mr. Goodwin joins the Company from the UK Government's Cabinet Office, where he last oversaw a transformation programme for 330,000 employees under the Arm's-Length Bodies and was responsible for policy advice to the Cabinet Office and His Majesty's Treasury Ministers. The appointment of Mr. Goodwin to oversee everything People and HR related provides the Company with an opportunity to streamline the company at Group level for operational and financial efficiency and Physitrack therefore at the same time also announces that it will reduce its C-suite with two people, whose roles overlap significantly with that of the Head of People function. Further to the appointment of Jack Goodwin, departing the C-suite as of but remaining with the Company for a transition period are Mr. Andrew Knox, Group Chief Operating Officer and Mr. Ryan Ebert, Chief Commercial Officer, Wellness. Ryan and Andrew will both ensure a smooth handover to Mr. Goodwin as the Physitrack Group continues on its journey.
お知らせ • May 04Physitrack PLC Approves Election of Anne-Sophie D'andlau as DirectorPhysitrack PLC approved election of Anne-Sophie D'Andlau as a Director of the Company at the Annual General Meeting held on May 3, 2023.
Reported Earnings • May 03First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: €3.73m (up 45% from 1Q 2022). Net loss: €65.6k (loss narrowed 55% from 1Q 2022). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Healthcare Services industry in Sweden.
Recent Insider Transactions • Apr 05Independent Non-Executive Director recently bought kr56k worth of stockOn the 31st of March, Anne-Sophie d'Andlau bought around 4k shares on-market at roughly kr13.92 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold kr10.0m more in shares than they bought in the last 12 months.
Major Estimate Revision • Mar 31Consensus EPS estimates upgraded to €0.025 lossThe consensus outlook for fiscal year 2022 has been updated. 2022 losses forecast to reduce from -€0.037 to -€0.025 per share. Revenue forecast steady at €12.4m. Healthcare Services industry in Sweden expected to see average net income growth of 176% next year. Consensus price target broadly unchanged at kr40.13. Share price rose 12% to kr14.50 over the past week.
Reported Earnings • Mar 02Full year 2022 earnings released: EPS: €0.01 (vs €0.06 loss in FY 2021)Full year 2022 results: EPS: €0.01 (up from €0.06 loss in FY 2021). Revenue: €12.5m (up 60% from FY 2021). Net income: €92.3k (up €907.4k from FY 2021). Profit margin: 0.7% (up from net loss in FY 2021). The move to profitability was driven by higher revenue. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Sweden.
分析記事 • Jan 29Be Wary Of Physitrack (STO:PTRK) And Its Returns On CapitalDid you know there are some financial metrics that can provide clues of a potential multi-bagger? Amongst other things...
お知らせ • Jan 27Physitrack PLC Appoints Nick McClelland to Take on A New Role as Chief Growth OfficerPhysitrack PLC appointed Nick McClelland from Mercer to take on a new role as Chief Growth Officer of Champion Health with the objective of further accelerating the growth of Group's B2B Wellness division. Nick McClelland will lead and build on Champion Health's sales team for B2B sales of Champion's rapidly growing Employee Wellbeing solution to Enterprises as well as further develop Group level business development to continue accelerating the growth of both Champion Health and the Physitrack Group. Prior to joining Champion Health, Nick McClelland was Chief Growth Officer of Mercer UK, part of $82 billion market capitalisation global insurance giant Marsh McLennan, and prior to that led the commercial efforts of JLT Employee Benefits and Thompsons Online Benefits, which provided technology-led employee benefit and wellness solutions to Enterprises globally before both companies were acquired by Mercer. Nick is set to commence in his new role on 1 February 2023.
Board Change • Jan 01High number of new and inexperienced directorsThere are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Co-Founder, CEO & Executive Director Henrik Molin is the most experienced director on the board, commencing their role in 2012. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Dec 21Physitrack PLC Announces the Appoints Anne-Sophie d'Andlau as Board MemberPhysitrack PLC announced the appointment of Mrs. Anne-Sophie d'Andlau to the board of directors as an independent non-executive director, effective immediately. Mrs. d'Andlau has also been appointed as a member of Physitrack Plc's nomination and audit committees. Anne-Sophie d'Andlau is the co-founder of CIAM, a corporate events-focused investment management firm that takes an active approach to equity-based investment strategies. Prior to co-founding CIAM, Anne-Sophie was the Head of Event Driven Strategies at Systeia Capital Management in Paris 2001-2008. Prior to that, Anne-Sophie spent six years with PwC in Paris and New York focused on audit, due diligence and M&A advisory. She has a degree in Corporate Finance from NEOMA Business School.
Reported Earnings • Nov 08Third quarter 2022 earnings released: EPS: €0.001 (vs €0.07 loss in 3Q 2021)Third quarter 2022 results: EPS: €0.001 (up from €0.07 loss in 3Q 2021). Revenue: €3.37m (up 69% from 3Q 2021). Net income: €16.7k (up €898.8k from 3Q 2021). Profit margin: 0.5% (up from net loss in 3Q 2021). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Healthcare Services industry in Sweden.
お知らせ • Nov 07+ 4 more updatesPhysitrack PLC to Report Q2, 2023 Results on Aug 15, 2023Physitrack PLC announced that they will report Q2, 2023 results on Aug 15, 2023
分析記事 • Oct 29Physitrack (STO:PTRK) Will Be Hoping To Turn Its Returns On Capital AroundTo find a multi-bagger stock, what are the underlying trends we should look for in a business? In a perfect world, we'd...
お知らせ • Aug 31Henrik Molin, Chief Executive Officer and Co-founder of Physitrack PLC acquired an additional 4.3% stake in Physitrack PLC (OM : PTRK) from Nathan Skwortsow, co-founder of Physitrack PLC for €1 million.Henrik Molin, Chief Executive Officer and Co-founder of Physitrack PLC acquired an additional 4.3% stake in Physitrack PLC (OM : PTRK) from Nathan Skwortsow, co-founder of Physitrack PLC for €1 million on August 29, 2022. Under the terms of the transaction, Henrik Molin acquired 0.7 million shares Physitrack PLC from Nathan Skwortsow. As a result of the transaction, Henrik Molin boosts its ownership to 24.7% and reduces Nathan Skwortsow’s ownership to 17.8%. in Physitrack PLC.Henrik Molin, Chief Executive Officer and Co-founder of Physitrack PLC completed the acquisition of an additional 4.3% stake in Physitrack PLC (OM : PTRK) from Nathan Skwortsow, co-founder of Physitrack PLC on August 29, 2022.
Reported Earnings • Aug 25Second quarter 2022 earnings released: €0.02 loss per share (vs €0.011 loss in 2Q 2021)Second quarter 2022 results: €0.02 loss per share (down from €0.011 loss in 2Q 2021). Revenue: €3.05m (up 76% from 2Q 2021). Net loss: €421.0k (loss widened 240% from 2Q 2021). Over the next year, revenue is forecast to grow 48%, compared to a 16% growth forecast for the Healthcare Services industry in Sweden.
お知らせ • Aug 11Physitrack plc Recruits Announces Management ChangesPhysitrack PLC boosts its management team and recruits Michal Wegrzyn from Zendesk. Michal Wegrzyn will take on a new role as Head of Engineering at Physitrack. As a result of the recruitments, co-founder and CTO Nathan Skwortsow will take on a new position focused on sourcing and developing new business ventures on behalf of the company. Michal Wegrzyn, who prior to joining Physitrack was an Engineering Manager at NYSE-listed$10bln market leader in customer support SaaS provider Zendesk, has been recruited as Head of Engineering. Michal will lead a new team of in-house Ruby on Rails, Mobile and DevOps developers, as Physitrack transitions away from its previous inhouse/outsource hybrid software development model. The new setup will not only benefit Physitrack from an efficiency and cultural standpoint but will also optimize the cost of investments in Physitrack's platform.As a result of the recruitments, co-founder and CTO Nathan Skwortsow will take on a new position in Physitrack's management team focused on sourcing and developing new business ventures on behalf of the company.
Recent Insider Transactions • Jun 03Chief Operating Officer recently bought kr56k worth of stockOn the 30th of May, Andrew Knox bought around 1k shares on-market at roughly kr42.99 per share. This was the largest purchase by an insider in the last 3 months. Andrew has been a buyer over the last 12 months, purchasing a net total of kr108k worth in shares.
Reported Earnings • May 26First quarter 2022 earnings: Revenues miss analyst expectationsFirst quarter 2022 results: Revenue: €2.58m (up 63% from 1Q 2021). Net loss: €145.7k (down 177% from profit in 1Q 2021). Revenue missed analyst estimates by 2.9%. Over the next year, revenue is forecast to grow 58%, compared to a 19% growth forecast for the industry in Sweden.
お知らせ • May 08Physitrack PLC (OM:PTRK) acquired Champion Health Ltd from Harry Bliss and Ricky Bailey for £10.4 million.Physitrack PLC (OM:PTRK) acquired Champion Health Ltd from Harry Bliss and Ricky Bailey for £10.4 million on May 6, 2022. Physitrack will pay a total cash consideration of £2.5 million upfront for the acquisition, and a further potential aggregate earn-out consideration of up to £7.894 million over four years, subject to Champion achieving stretching growth and profitability targets in that period. The deal is financed with cash. Post-completion, Champion's successful wellbeing platform and innovative technology will continue to be accessible as a standalone product and will over time see the integration of Physitrack's Access ecosystem. Champion Health Ltd had gross assets of €0.3 million (£0.25 million) and revenue of €0.1 million (£0.08 million) for the year ended December 31, 2021. The management team of Champion, including co-founders Harry Bliss, Chief Executive Officer of Champion and Ricky Bailey, Chief Development Officer of Champion, their team of wellbeing and tech experts, as well as their network of skilled contributors and certified health practitioners will join Physitrack. The closing of the transaction is not subject to any closing conditions, including no regulatory approvals. The acquisition of Champion is a financially accretive deal. Paul Berwin and team of Berwins LLP acted as legal advisor to the founder shareholders. Physitrack PLC (OM:PTRK) completed the acquisition of Champion Health Ltd from Harry Bliss and Ricky Bailey on May 6, 2022.
Reported Earnings • Mar 01Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2021 results: €0.06 loss per share (down from €0.069 profit in FY 2020). Revenue: €7.81m (up 156% from FY 2020). Net loss: €815.0k (down 218% from profit in FY 2020). Revenue exceeded analyst estimates by 1.6%. Earnings per share (EPS) missed analyst estimates. Over the next year, revenue is forecast to grow 60%, compared to a 17% growth forecast for the industry in Sweden.
Recent Insider Transactions • Feb 26Chief Financial Officer recently bought kr62k worth of stockOn the 24th of February, Charlotte Goodwin bought around 1k shares on-market at roughly kr45.00 per share. This was the largest purchase by an insider in the last 3 months. This was Charlotte's only on-market trade for the last 12 months.
お知らせ • Feb 25+ 1 more updatePhysitrack PLC (OM:PTRK) acquired Wellnow Group GmbH from Axel Springer Plug and Play Accelerator GmbH and Tengelmann Ventures Management GmbH for €11.5 million.Physitrack PLC (OM:PTRK) acquired Wellnow Group GmbH from Axel Springer Plug and Play Accelerator GmbH and Tengelmann Ventures Management GmbH for €11.5 million on February 23, 2022. Physitrack will pay a total cash consideration of €2.5 million for the acquisition and a further potential aggregate earn-out consideration of up to €9 million over four years, subject to Wellnow achieving stretching growth targets in that period that are in alignment with Physitrack’s. In the twelve months ending December 31, 2021, Wellnow delivered revenue of €0.4 million. At 31 December 2021, Wellnow´s gross assets were EUR 0.3 million. Physitrack PLC (OM:PTRK) completed the acquisition of Wellnow Group GmbH from Axel Springer Plug and Play Accelerator GmbH and Tengelmann Ventures Management GmbH on February 23, 2022.
Reported Earnings • Jan 27Full year 2021 earnings: EPS exceeds analyst expectationsFull year 2021 results: €0.05 loss per share (down from €0.069 profit in FY 2020). Revenue: €7.72m (up 153% from FY 2020). Net loss: €635.0k (down 192% from profit in FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 75%. Over the next year, revenue is forecast to grow 48%, compared to a 19% growth forecast for the industry in Sweden.
お知らせ • Jan 27Physitrack PLC Provides Earnings GuidancePhysitrack PLC announced that the company's aims to achieve annual organic sales growth exceeding 30% in the medium term, further supplemented by impact from future add-on acquisitions.
Valuation Update With 7 Day Price Move • Jul 04Investor sentiment improved over the past weekAfter last week's 21% share price gain to €50.40, the stock trades at a trailing P/E ratio of 72.3x. Average trailing P/E is 45x in the Healthcare Services industry in Europe.
お知らせ • Jun 19Physitrack PLC has completed an IPO in the amount of SEK 175 million.Physitrack PLC has completed an IPO in the amount of SEK 175 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 4,375,000 Price\Range: SEK 40